---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125329"
form_type: "8-K"
ticker: "GUTS"
cik: "0001572616"
company_name: "FRACTYL HEALTH, INC."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:54:05.275505+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fractyl Health Q3 net loss $23.2M; cash $84.7M; Revita studies on track

## Summary
- Net loss $23.2M vs $15.7M YoY; R&D expense $19.0M (up from $9.4M) on clinical progress.
- Cash and equivalents $84.7M; expected to fund operations into Q4 2025.
- REMAIN-1 mid-point analysis expected Q2 2025; REVEAL-1 open-label data start Q4 2024.
- REVITALIZE-1 topline data expected mid-2025; RJVA-001 CTA submission by YE 2024.
- Nominated RJVA-002, first smart GIP/GLP-1 pancreatic gene therapy candidate for obesity.

## SEC filing metadata
- accession: 0000950170-24-125329
- form_type: 8-K
- ticker: GUTS
- cik: 0001572616
- company_name: FRACTYL HEALTH, INC.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1572616/000095017024125329/0000950170-24-125329-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1572616/000095017024125329/guts-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125329
- JSON: https://secwatch.observer/filing/0000950170-24-125329.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125329.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.